Cardinal opens cyclotron in Georgia

Justine Varieur Cadet | | Health Imaging | Molecular Imaging
Cardinal Health has opened its first cyclotron facility in the state of Georgia, expanding its capability to manufacture molecular imaging biomarkers that aid in the early diagnosis, monitoring and treatment of cancer, neurological disorders and heart disease.

Cardinal said its Augusta cyclotron facility will be located near its existing nuclear pharmacy in Augusta, where the company will dispense PET imaging agents in patient-specific doses. The company now operates a nationwide network of 36 cyclotrons, with its Charlotte, N.C., cyclotron being the closest to Augusta.

The new cyclotron also will support molecular imaging research in nearby hospitals and universities, and will be available to support clinical trials that evaluate the effectiveness of new PET imaging agents, according to the Dublin, Ohio-based company.

Justine Varieur Cadet

Related Content

Dementia cases are about to skyrocket—how will this affect imaging demand?
Experts update AUC for amyloid, tau PET imaging for first time in more than a decade
Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.